Skip to content
Specialized Packaging Market Intelligence and Strategic AdvisoryPackaging Intelligence. Clearer Decisions. Stronger Growth.
SPI Buyers Database

Pharma and health

Pfizer packaging profile

Pfizer is a pharmaceutical company. Its packaging page sets qualitative aims to cut packaging materials and run take-back programs, without numeric targets.

By the SPI teamSources consulted 13 October 2026Status: LiveSourced from company reports; not yet re-checked by a second SPI team member.How this database works
Company profile

At a glance

Legal name
Pfizer Inc.1
Incorporated
Delaware, USA (incorporated 2 June 1942)1
Headquarters
66 Hudson Boulevard East, New York, New York 10001-2192, USA1
Listing
New York Stock Exchange: PFE1
Financial year end
31 December (non-U.S. subsidiaries repor1
Total revenues
USD 62,579 million (2025); USD 63,627 million (2024)2
Organic sales growth
-2% (2025)2
Employees
75,0007
Markets
Medicines and vaccines supplied to approximately 200 countries and territories; revenues above USD 500 million in 12 countries outside the U.S. in 20251
Note
36 manufacturing sites worldwide (investor fact sheet).7
Note
Top products by FY2025 revenue (USD million): Eliquis 7,961; Prevnar family 6,494; Vyndaqel family 6,380; Comirnaty 4,367; Ibrance 4,122; Paxlovid 2,362; Xtandi 2,194; Padcev 1,940; Abrysvo 1,033.2
End uses
Pharma and health
The business

Business and brands

Brands by category

Primary Care (internal medicine, vaccines, anti-infectives)2
  • Eliquis
  • Prevnar family
  • Abrysvo
  • Comirnaty
  • Paxlovid
Specialty Care2
  • Vyndaqel family
Oncology2
  • Ibrance
  • Xtandi
  • Padcev
Markets

Geographic footprint

  • U.S. revenues were USD 37,078 million and international revenues USD 25,501 million in FY2025 (41% international, up from 39% in 2024).2
  • Revenues exceeded USD 500 million in 12 countries outside the U.S. in 2025 (countries not named in the section read).1
As the company reports it

Packaging profile

Formats and materials the company itself reports using, in its own reporting. No pack specifications, volumes or supplier names beyond what it has published.

FormatMaterialWhat the company reports
Tertiary shipment packagingMixed3R Circular Program prioritises reduction, reuse and recycling of high-volume tertiary shipment materials4
Cold chain blankets, palletsThermal blankets, woodPiloting reuse of cold chain thermal blankets and lighter-weight wooden pallets4
All packagingNot specifiedPackaging aims: eliminate and reduce packaging materials for existing products as regulations allow; minimise and optimise packaging for new launches; select materials with lower GHG profiles, fewer chemicals of concern and more recycled material; take-back programs for packaging with suppliers5
Design toolNot specifiedInternal life cycle assessment tool used by package designers5

Reporting scope: The 2025 Impact Report covers 1 January to 31 December 2025 unless otherwise noted. No packaging tonnage or packaging KPIs are reported in the sections read.4

Packaging suppliers

No packaging supplier relationship is publicly announced in the sources reviewed. The packaging page refers to collaboration and take-back programs with suppliers without naming them.

Industry and recycling partners named by the company4

  • Pharmaceutical Supply Chain Initiative (PSCI), founding member
The register

Packaging targets and progress

Targets and progress are taken from each company's own published reports, with a quote and a link on its page. Status shows met or missed only where the company has reported the result. No contacts, purchase volumes, supplier relationships or pack specifications are listed.

Other Not reported Sourced, not yet re-checked

Eliminate and reduce packaging materials for existing products (no numeric target or year)

Latest reported: Not reported

From the source“Eliminate and reduce packaging materials as regulations allow and technology enables for existing products.”

Pfizer – Packaging

Other Met By 2025 Sourced, not yet re-checked

64% of purchased goods and services suppliers by spend to set science-based GHG reduction targets by 2025

Latest reported: 72% (2025)

From the source“driving 64% of our suppliers of goods and services by spend to also set science-based GHG emission reduction goals by 2025”

Pfizer – 2025 Impact Report

Other In progress By 2040 Sourced, not yet re-checked

Reduce value chain (Scope 3) emissions by 90% by 2040 vs 2019

Latest reported: Not reported for Scope 3 total; SBTi validation paused in 2024

From the source“By 2040, we aim to decrease our company's GHG emissions by 95% and our value chain emissions by 90% from 2019 levels”

Pfizer – 2025 Impact Report

Commitments

Commitments and baselines

Every packaging and supply-chain commitment the company has published, with its baseline and the latest progress it reports. Status says met or missed only where the company states the result.

CommitmentByBaselineLatest reportedStatus
Green Journey packaging aimsEliminate and reduce packaging materials for existing products as regulations allow and technology enables; minimise packaging for new launches; maximise recycled materials (no numeric target or year)5–Not reportedIn progress
Net zero 204064% of purchased goods and services suppliers by spend to set science-based GHG reduction targets by 20258Purchased goods and services suppliers include packaging suppliers (SPI note)2025–72% of suppliers (2025)Met
Net zero 2040Reduce value chain (Scope 3) emissions by 90% by 2040 vs 2019; Scope 1 and 2 down 46% by 2030 and 95% by 2040620402019Scope 1 and 2 down 40.9% vs 2019; SBTi validation of the net-zero target paused in 2024 (2025)In progress

Initiatives and pacts the company names

  • Pharmaceutical Supply Chain Initiative (PSCI), founding member and active participant4 as of 2 Jun 2026
SPI analysis

What the commitments mean

Pfizer's packaging commitments are qualitative. Its Green Journey packaging page sets four aims without numbers or dates: eliminate and reduce packaging on existing products as regulations allow and technology enables; minimise and optimise packaging for new launches; choose materials with lower greenhouse gas profiles, fewer chemicals of concern and more recycled material; and run take-back programmes for packaging with suppliers5. Package designers use an internal life cycle assessment tool to estimate the impact of designs5.

The numeric targets shown in the register on this page are climate targets. The goal that 64% of purchased goods and services suppliers by spend set science-based greenhouse gas targets by 2025 is a supplier-climate target, not a packaging target: it counts suppliers of every kind by spend and measures whether they have set emissions goals, not packaging material, weight or recyclability8. Packaging suppliers are among those counted, but meeting it shows nothing about Pfizer's packaging. The same holds for the 2040 net-zero goal, which includes a 90% cut in value chain emissions from 20196.

The packaging work disclosed in the 2025 Impact Report, published on 2 June 2026, is in distribution: the 3R Circular Program for high-volume tertiary shipment materials, with pilots of reusable cold chain thermal blankets and lighter wooden pallets4. Pfizer is a founding member of the Pharmaceutical Supply Chain Initiative4, an industry body for supplier standards rather than a packaging coalition.

SPI analysis

Progress against targets

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

None of Pfizer's packaging aims has a target value, so there is no packaging progress to calculate, and the 2025 Impact Report gives no packaging tonnage, material split or packaging KPI4.

Supplier science-based targets: 72% of suppliers by spend in 2025 against the 64% goal8. SPI calculation: 8 points above the goal. The goal is met, but it is a climate engagement result and should not be read as packaging progress, because it measures suppliers' target-setting rather than any change in the cartons, shippers or pallets Pfizer uses.

Operational emissions: Scope 1 and 2 were 40.9% below 2019 in 2025, against 46% by 20306. SPI calculation: 5.1 points remain over five years, about 1 point a year. Scope 3 progress toward the 90% by 2040 goal is not stated in the report sections cited, and Pfizer paused SBTi validation of its net-zero target in 20246, so value chain pace, where purchased packaging sits, cannot be tested.

Tertiary packaging pilots: the report describes pilots, not quantities, so SPI cannot size the reusable blanket or pallet programmes.

Scale: total revenues were USD 62,579 million in 2025 against USD 63,627 million in 20242, with medicines and vaccines supplied to about 200 countries and territories from 36 manufacturing sites17. Packaging use follows volumes, but no volume measure is reported.

Last 24 months

Recent packaging developments

  1. 2025 Impact Report: 3R Circular Program focuses on reducing, reusing and recycling high-volume tertiary shipment materials, with pilots reusing cold chain thermal blankets and lighter-weight wooden pallets; 72% of suppliers by spend have science-based targets against a 64% goal.4

SPI analysis

Regulatory exposure

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

Basis: Presence is taken from subsidiaries listed in Exhibit 213 and the 10-K statement that medicines and vaccines are supplied to about 200 countries and territories1. Pfizer sells prescription medicines and vaccines, so beverage deposit and food-contact PFAS rules do not apply. Many packaging laws give medicinal products partial exemptions (for example PPWR recyclability and recycled-content exemptions for medicinal immediate packaging, the UK Plastic Packaging Tax exemption for immediate packaging of licensed human medicines, and drug-packaging exemptions in several U.S. state EPR laws); these were not checked rule by rule. Rule IDs are from the SPI Regulation Tracker. Applicability is SPI's reading, not legal advice.

JurisdictionRules in the Regulation Tracker
European UnionSubsidiaries in many Member States, for example Pfizer Deutschland GmbH, Pfizer, S.L.U.3

Secondary and transport packaging (cartons, shippers) is in scope; immediate medicinal packaging has exemptions from some PPWR design and recycled-content rules.

GermanyPfizer Deutschland GmbH3
FrancePfizer Holding France3

Applicability of Triman labelling to medicines not checked.

SpainPfizer, S.L.U.3

Any exemption for medicinal packaging under the Spanish plastic tax not checked.

AustriaPfizer Manufacturing Austria G.m.b.H.3

Tracker rule is beverage deposit only.

IrelandPfizer Healthcare Ireland Unlimited Company3

Tracker rule is beverage DRS only.

PortugalLaboratórios Pfizer, Lda.3

Tracker rule is beverage DRS only.

PolandPfizer Polska Sp. z.o.o.3

Tracker rule is beverage DRS only.

United KingdomHospira UK Limited and other UK subsidiaries3

Immediate packaging of licensed human medicines is exempt from Plastic Packaging Tax; secondary and transport plastic is not.

United StatesHeadquarters1

Several state EPR laws exempt packaging for drugs and medical devices; exemptions not checked per state.

CanadaTrillium Therapeutics ULC and other Canadian subsidiaries3
IndiaPfizer Healthcare India Private Limited3

Pharmaceutical exemptions from recycled-content and reuse obligations not checked.

ChinaPfizer (Beijing) Research and Development Co., Ltd and others3

GB 23350-2021 covers food and cosmetics, not medicines.

JapanPfizer Japan Inc.3
AustraliaHospira Adelaide Pty Ltd3

Proposed national EPR scheme.

New ZealandPfizer New Zealand Limited3

Tracker rules are single-use plastic item phase-outs; no direct match found.

VietnamPFIZER (VIETNAM) LIMITED COMPANY3
PhilippinesHospira Philippines, Inc.3
IndonesiaPT. Pfizer Indonesia3
ChilePfizer Chile S.A.3
ColombiaPfizer S.A.S.3
BrazilPfizer Brasil Ltda.3
KenyaPfizer Laboratories Limited3
South AfricaPfizer Laboratories (Pty) Limited3
United Arab EmiratesPfizer Gulf FZ-LLC3

Dubai rule targets single-use plates, cutlery, cups and lids; no direct match.

Plastic taxes: Plastic taxes in the tracker: UK Plastic Packaging Tax (PR-GB-001), where immediate packaging of licensed human medicines is exempt but secondary and transport plastic is not, and Spain's non-reusable plastic packaging tax (PR-ES-001), where medicinal exemptions were not checked. The EU plastic own resource (PR-EU-017) is paid by Member States, not by companies.

SPI analysis

Exposure by market

United Kingdom

Hospira UK Limited and other UK subsidiaries are listed in Exhibit 213. Immediate packaging of licensed human medicines is outside PR-GB-001, but plastic secondary and transport packaging such as shipper liners is taxable when it holds under 30% recycled plastic. PR-GB-002 and PR-GB-003 set EPR reporting and modulated fees on packaging placed on the UK market.

United States

Pfizer is headquartered in New York, with U.S. revenues of USD 37,078 million in 20252. Cartons, shippers and pallets in Oregon, Colorado, California and Washington come under PR-US-002, PR-US-003, PR-US-004 and PR-US-008 unless a state drug or medical device exemption applies. The 3R work on tertiary materials bears most directly on these laws.

European Union

Subsidiaries across the EU include Pfizer Deutschland GmbH and Pfizer, S.L.U.3. The PPWR (PR-EU-001) reaches secondary cartons and transport packaging, and PR-EU-009 caps empty space in transport packaging at 50% from 2030, which matters for cold chain shippers. Medicinal immediate packaging has exemptions from some PPWR design and recycled-content rules.

Germany

Pfizer Deutschland GmbH is listed3. PR-DE-001, the VerpackDG in force from 12 August 2026, requires producers selling packaged goods in Germany to register in the LUCID packaging register and finance recycling through system participation, which covers the sales packaging around medicines.

India

Pfizer Healthcare India Private Limited is listed3. PR-IN-001 requires brand owners and importers of plastic-packaged goods to register on CPCB's portal and meet EPR targets; how PR-IN-002 and PR-IN-003 treat pharmaceutical packaging was not checked.

Kenya

Pfizer Laboratories Limited is listed in Kenya3. PR-KE-002, Legal Notice 176 of 2024, requires producers of plastic, paper, glass and carton packaging to register and operate through compliance schemes, with existing producers given six months from commencement on 4 November 2024 to apply.

SPI analysis

What this means for packaging suppliers

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

Pfizer publishes no numeric packaging targets, so its packaging demand signals come from qualitative aims and from its climate programme. The clearest signal is in transport and cold chain packaging: the 2025 Impact Report says Pfizer is prioritising reduction, reuse and recycling of high-volume tertiary shipment materials and piloting reusable thermal blankets and lighter wooden pallets. Its packaging page also asks for lower-carbon materials, fewer chemicals of concern, more recycled content and take-back programs run with suppliers. Because 72% of suppliers by spend already have science-based climate targets and Pfizer aims for a 90% cut in value chain emissions by 2040, packaging suppliers should expect to be asked for emissions data and reduction plans. Primary packaging for medicines is tightly regulated and changes slowly, but secondary cartons, shippers and pallets in the EU, UK, U.S. EPR states and India sit inside packaging laws that partly exempt medicines. No supplier relationship has been publicly announced, so this describes demand signals, not who supplies.

Questions

Questions

Does Pfizer have packaging targets?

No numeric packaging target or target year appears on Pfizer's packaging page or in its 2025 Impact Report, published on 2 June 202654. Its aims are to cut packaging on existing products, optimise packaging for new launches, use lower-carbon and recycled materials, and run take-back programmes with suppliers.

Is Pfizer's 2025 supplier target a packaging target?

No. The goal that 64% of purchased goods and services suppliers by spend set science-based greenhouse gas targets by 2025 is a supplier-climate target8. Pfizer reported 72% in 2025, but the measure says nothing about packaging materials, weight or recyclability.

What packaging is Pfizer reducing?

The 2025 Impact Report focuses on high-volume tertiary shipment materials under the 3R Circular Program4. Pfizer is piloting reuse of cold chain thermal blankets and lighter-weight wooden pallets. No quantities had been published as of October 2026.

How does Pfizer assess packaging designs?

Pfizer's package designers use an internal life cycle assessment tool to estimate the environmental impact of designs5. It supports the aim of choosing materials with lower greenhouse gas profiles, but no results from it were published in the sources read on 14 October 2026.

Which Pfizer climate goals reach packaging suppliers?

Pfizer aims to cut value chain emissions 90% from 2019 by 20406. Purchased goods include packaging, so packaging suppliers fall inside that Scope 3 goal. Pfizer paused SBTi validation of the net-zero target in 2024.

Limits

Data gaps

What the sources reviewed do not show, or what we could not confirm. Know something we have missed? Tell the SPI team and we will check it.

  • No numeric packaging targets, packaging tonnage or material split are published in the sources reviewed.
  • No packaging supplier relationships are publicly announced in the sources reviewed.
  • Employee count is taken from the investor fact sheet without an as-of date; the 10-K 'Our People' section could not be read (fetch truncated).
  • 10-K Environmental Matters section could not be read (fetch truncated); 10-K filing date not confirmed.
  • No packaging press releases from October 2024 to October 2026 were found.
  • Brand list is limited to top products named in the earnings release; full product list not compiled.
  • Memberships of Ellen MacArthur Foundation, Plastics Pacts or CGF coalitions were not found and are probably not applicable.
  • Medicinal-packaging exemptions under each tracked rule were not checked rule by rule.
  • Scope 3 total progress against the 2019 baseline is not stated in the sections read.
Evidence

Sources

  1. Pfizer Inc. – Form 10-K for fiscal year 2025Regulatory filing · published 2026 · consulted 13 Oct 2026
  2. Pfizer – Fourth-quarter and full-year 2025 earnings releaseRegulatory filing · published 3 Feb 2026 · consulted 13 Oct 2026
  3. Pfizer – Exhibit 21, Subsidiaries (FY2025 10-K)Regulatory filing · published 2026 · consulted 13 Oct 2026
  4. Pfizer – 2025 Impact ReportCompany publication · published 2 Jun 2026 · consulted 13 Oct 2026
  5. Pfizer – Packaging (Green Journey)Company publication · consulted 13 Oct 2026
  6. Pfizer – Environmental SustainabilityCompany publication · consulted 13 Oct 2026
  7. Pfizer – Investor fact sheetCompany publication · published 4 Aug 2026 · consulted 13 Oct 2026
  8. Pfizer – Pfizer's 2025 Impact Report Highlights Progress Across Patients, Planet, and Responsible BusinessCompany publication · consulted 13 Oct 2026

SPI analysis sections written by the SPI team on 14 October 2026. Not company-reported, not legal advice.

Targets in the register above link to their own source. Facts are summarised in the SPI team's words; quotes are marked.

Method

About the SPI Buyers Database

Purpose
To help packaging makers and suppliers see what large buyers have committed to publicly, by end use and region, and how far they have got.
Coverage
42 large brand owners and retailers so far, chosen for their size in packaging demand. It is not a complete list of buyers in any market.
Data sources
Each company's own sustainability, annual and ESG reports, press releases and filings, plus official sources where a pledge was made to a public body.
SPI Methodology
For each target we record the wording, the target year, the latest progress the company reports and a short quote from the source. Status says met or missed only when the company states the result; otherwise it shows in progress or not reported.
Limitations
Companies report on different bases and years. Headquarters countries and end uses are assigned by the SPI team and are not separately sourced. Rows have not yet been re-checked by a second SPI team member. No contacts, purchase volumes, supplier relationships or pack specifications are included.
Access
Free to read and to download as CSV. For an analysis of a buyer group for your products, ask for a buyer briefing.
ClosingAsk the SPI team

Ask the SPI team

Selling packaging to these companies?

We map a buyer's public commitments and deadlines to the materials and formats they affect, and assess the opportunity for converters and material suppliers.

Prefer email? Write to sales@strategicpackaginginsights.com.

Questions people bring
  1. Q1

    Which material should replace our current pack?

    We compare the realistic alternatives on recyclability evidence, regulatory fit and cost direction, and say where the evidence is thin.

  2. Q2

    How do our targets compare with our peers'?

    We benchmark the public packaging commitments and reported progress of the companies you name, each with its source.